Labcorp Q4 Earnings Call Highlights

Management also highlighted continued strength in specialty and esoteric testing. Schechter said esoteric testing grew double digits in 2025 and remains a key growth engine, including in the company’s central laboratory business serving clinical trials. CFO Julia Wang added that esoteric testing as a share of total testing revenue increased over time, from 37.5% in the first quarter of 2023 to 41.5% in the fourth quarter of 2025.During the fourth quarter, Labcorp entered into an agreement to acquire select ...